Okami Medical Announces $45 Million Financing and New CEO Appointment to Drive Next Phase of Growth - Gilde Healthcare

Okami Medical Announces $45 Million Financing and New CEO Appointment to Drive Next Phase of Growth

20. November 2025
Aliso Viejo, Ca. (United States)

Okami Medical, a medical technology company pioneering novel vascular embolization solutions, today announced the successful close of an oversubscribed $45M financing led by new investor Gilde Healthcare with participation from existing investors including Vensana Capital and U.S. Venture Partners.

Proceeds from the financing will be used to expand the company’s commercial footprint and advance its clinical programs in support of Okami’s mission to improve outcomes for patients suffering from vascular disease. The funding will also support continued innovation of the company’s versatile, intuitive devices designed for the occlusion of peripheral vessels.

Concurrent with the financing, Drew Hykes, former CEO of Inari Medical, was appointed President and CEO of Okami, while Bill Hoffman was appointed Chairman of the Board.

“I’m honored to join the Okami team and have been deeply impressed by the clinical performance and versatility of the LOBO vascular occluder across a wide range of anatomies,” said Drew Hykes, Chief Executive Officer of Okami Medical. “I look forward to working with this talented team to accelerate our commercial expansion, advance our innovation pipeline, and bring this important technology to more physicians and patients.”

As part of the financing, Geoff Pardo and Susana Amorim of Gilde Healthcare have joined Okami Medical’s Board of Directors. “We have followed Okami for years and have been impressed by the strength of its technology and the scale of its market opportunity,” said Geoff Pardo, General Partner at Gilde Healthcare. “We are pleased to partner with Drew again following our success at Inari and to collaborate with a highly experienced syndicate. We believe Okami’s LOBO platform has the potential to transform treatment and significantly improve outcomes for patients with serious unmet needs.”

About Okami Medical
Stopping flow. Restoring lives. This is the mission of Okami Medical, Inc., a privately held medical device company committed to addressing the evolving needs of patients and physicians through the development of innovative, versatile, and intuitive devices for the occlusion of peripheral vessels. The company was created in 2017 by Inceptus Medical, a medical device incubator. For more information, please visit www.okamimedical.com.

About Gilde Healthcare
Gilde Healthcare is a specialized healthcare investor managing €2.6 billion across two fund strategies: Venture&Growth and Private Equity. The Venture&Growth fund of Gilde Healthcare invests in fast growing companies active in therapeutics, medtech and digital health, based in Europe and North America. The Private Equity fund of Gilde Healthcare participates in profitable lower mid-market healthcare companies based in North-Western Europe. For more information, please visit www.gildehealthcare.com.

Mehr neuigkeiten

Gilde Healthcare legt Climate Solutions Fonds auf und erzielt beim ersten Closing €250 Mio.

Mit Commitments internationaler Pensionsfonds, Banken, Fund-of-Funds, Endowments und Family Offices erreicht Gilde Healthcare ein erstes Closing in Höhe von €250 Mio Die Erweiterung um Climate Solutions baut auf Gilde Healthcare‘s Erfolgsbilanz im Bereich des Impact...
18. Februar 2026

Gilde Healthcare Company Big Health Secures Funding to Accelerate Adoption of Digital Mental Health Treatments

New investment fuels expansion as leading health systems adopt evidence-based digital care, driven by new billing codes and strong demand for proven mental health solutions. Big Health, a leading developer of digital treatments for the...
12. Februar 2026

Gilde Healthcare company SpyGlass Pharma announces pricing of initial public offering at NASDAQ

SpyGlass Pharma, Inc. (Nasdaq: SGP) (“SpyGlass Pharma”), a late-stage biopharmaceutical company, today announced the pricing of its initial public offering of 9,375,000 shares of its common stock at a public offering price of $16.00 per...
6. Februar 2026